Board Meeting Details

The Board of Directors meeting was held on Thursday, July 30, 2026, commencing at 05:30 PM (IST) and concluding at 06:15 PM (IST).

Key Decisions Approved

1. Approved unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Auditors for the quarter ended June 30, 2026

2. Approved allotment under ESOP Scheme 2020

Trading Window Update

Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015, the Trading Window for dealing in the Company's securities by Designated Persons shall reopen with effect from Monday, August 3, 2026.

Consolidated Financial Results (Q1 FY27)

Income Statement (₹ millions)

  • Revenue from operations: 10,631
  • Other income (net): 290
  • Total income: 10,921

Expenses (₹ millions)

  • Employee benefits expense: 6,591
  • Finance costs: 64
  • Depreciation and amortization expense: 441
  • Other expenses: 2,298
  • Total expenses: 9,394

Profitability (₹ millions)

  • Profit before exceptional item and tax: 1,527
  • Exceptional items (net): (203) [TCPA litigation provision]
  • Profit before tax: 1,527
  • Tax expense: 365 (Current tax: 293, Deferred tax: 72)
  • Profit for the period: 1,162

Other Comprehensive Income (₹ millions)

  • Total Other Comprehensive Income: 118
  • Total Comprehensive Income for the period: 1,280

Earnings Per Share

  • Basic EPS: ₹4.84
  • Diluted EPS: ₹4.81
  • Paid-up equity share capital: ₹481 million (Face value ₹2 each)

Standalone Financial Results (Q1 FY27)

Income Statement (₹ millions)

  • Revenue from operations: 3,407
  • Other income (net): 339
  • Total income: 3,746

Expenses (₹ millions)

  • Employee benefits expense: 2,217
  • Finance costs: 27
  • Depreciation and amortization expense: 114
  • Other expenses: 588
  • Total expenses: 2,946

Profitability (₹ millions)

  • Profit before tax: 800
  • Tax expense: 201 (Current tax: 178, Deferred tax: 23)
  • Profit for the period: 599
  • Total Comprehensive Income for the period: 607

Earnings Per Share

  • Basic EPS: ₹2.49
  • Diluted EPS: ₹2.48
  • Paid-up equity share capital: ₹481 million (Face value ₹2 each)

Segment Information

The Group has 2 reportable segments:

1. Enterprise Medical Solutions: Revenue ₹7,502 million, Segment result ₹716 million

2. Enterprise Commercial Solutions: Revenue ₹3,129 million, Segment result ₹1,197 million

Subsidiary Information

The consolidated results include financial results of 1 subsidiary and 10 step-down subsidiaries. Certain subsidiaries (representing total revenue of ₹413 million, loss after tax of ₹12 million, and other comprehensive loss of ₹18 million) were not reviewed by their auditors but were considered not material to the Group.

IPO Fund Utilization

As of June 30, 2026, the Company has fully utilized the IPO proceeds of ₹7,246 million as follows:

  • Repayment/prepayment of indebtedness of ILSL Holdings Inc.: ₹3,950 million
  • Funding capital expenditure requirements: ₹644 million
  • Technology, cybersecurity and cloud infrastructure: ₹350 million
  • General corporate purposes and inorganic growth: ₹2,302 million

Exceptional Item - TCPA Litigation

During FY2020-21, Indegene Inc. was named in a class action lawsuit in US District Court of New Jersey alleging non-compliance with Telephone Consumer Protection Act.

During FY2026, the matter progressed to mediation and the Group agreed to a mediator-proposed settlement framework providing for a maximum settlement amount of ₹417 million (USD 4.72 million). The Group recognized a provision of ₹203 million (USD 2.30 million) including estimated legal costs, disclosed as an exceptional item in Q4 FY26 results.

A term sheet for the settlement agreement dated May 25, 2026 has been signed, which will be formalized into a Settlement agreement post court approval.

Dividend Proposal

The Board of Directors, in its meeting on April 29, 2026, proposed a final dividend of ₹2.25 per equity share for FY2026, subject to shareholder approval at the ensuing AGM. If approved, this would result in a cash outflow of approximately ₹542 million.

Auditor Review

Deloitte Haskins & Sells issued an unmodified opinion on both standalone and consolidated financial results for the quarter ended June 30, 2026.

CFO Declaration

Suhas Prabhu, Chief Financial Officer, declared that the Statutory Auditors have submitted an unmodified opinion on the unaudited Financial Results for the quarter ended June 30, 2026.